Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) EBITDA (2018 - 2025)

Black Diamond Therapeutics' EBITDA history spans 6 years, with the latest figure at -$15.2 million for Q4 2025.

  • For Q4 2025, EBITDA rose 5.67% year-over-year to -$15.2 million; the TTM value through Dec 2025 reached $22.4 million, up 132.24%, while the annual FY2025 figure was $22.4 million, 132.24% up from the prior year.
  • EBITDA reached -$15.2 million in Q4 2025 per BDTX's latest filing, down from -$8.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $56.5 million in Q1 2025 to a low of -$35.1 million in Q3 2021.
  • Average EBITDA over 3 years is -$13.4 million, with a median of -$16.1 million recorded in 2024.
  • Peak YoY movement for EBITDA: crashed 154.26% in 2021, then soared 408.86% in 2025.
  • A 3-year view of EBITDA shows it stood at -$35.1 million in 2021, then soared by 54.28% to -$16.1 million in 2024, then increased by 5.67% to -$15.2 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's EBITDA are -$15.2 million (Q4 2025), -$8.3 million (Q3 2025), and -$10.6 million (Q2 2025).